IL131887A0 - Phospholipid prodrugs of anti-proliferative drugs - Google Patents

Phospholipid prodrugs of anti-proliferative drugs

Info

Publication number
IL131887A0
IL131887A0 IL13188799A IL13188799A IL131887A0 IL 131887 A0 IL131887 A0 IL 131887A0 IL 13188799 A IL13188799 A IL 13188799A IL 13188799 A IL13188799 A IL 13188799A IL 131887 A0 IL131887 A0 IL 131887A0
Authority
IL
Israel
Prior art keywords
proliferative drugs
phospholipid prodrugs
phospholipid
prodrugs
proliferative
Prior art date
Application number
IL13188799A
Other languages
English (en)
Original Assignee
Dpharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dpharm Ltd filed Critical Dpharm Ltd
Priority to IL13188799A priority Critical patent/IL131887A0/xx
Priority to US10/088,160 priority patent/US6774121B1/en
Priority to CA002382633A priority patent/CA2382633A1/en
Priority to JP2001522958A priority patent/JP2003514770A/ja
Priority to EP00960946A priority patent/EP1218013A4/en
Priority to PCT/IL2000/000562 priority patent/WO2001019320A2/en
Priority to IL14855400A priority patent/IL148554A0/xx
Priority to AU73093/00A priority patent/AU781507B2/en
Priority to NZ517522A priority patent/NZ517522A/en
Publication of IL131887A0 publication Critical patent/IL131887A0/xx
Priority to ZA200201081A priority patent/ZA200201081B/en
Priority to IL148554A priority patent/IL148554A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL13188799A 1999-09-14 1999-09-14 Phospholipid prodrugs of anti-proliferative drugs IL131887A0 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
IL13188799A IL131887A0 (en) 1999-09-14 1999-09-14 Phospholipid prodrugs of anti-proliferative drugs
PCT/IL2000/000562 WO2001019320A2 (en) 1999-09-14 2000-09-13 Phospholipid prodrugs of anti-proliferative drugs
CA002382633A CA2382633A1 (en) 1999-09-14 2000-09-13 Phospholipid prodrugs of anti-proliferative drugs
JP2001522958A JP2003514770A (ja) 1999-09-14 2000-09-13 抗増殖性医薬の燐脂質プロドラッグ
EP00960946A EP1218013A4 (en) 1999-09-14 2000-09-13 PHOPHOLIPID PRODUCTS OF CELL PROPAGATION INHIBITORS
US10/088,160 US6774121B1 (en) 1999-09-14 2000-09-13 Phospholipid prodrugs of anti-proliferative drugs
IL14855400A IL148554A0 (en) 1999-09-14 2000-09-13 Phospholipid prodrugs of anti-proliferative drugs
AU73093/00A AU781507B2 (en) 1999-09-14 2000-09-13 Phospholipid prodrugs of anti-proliferative drugs
NZ517522A NZ517522A (en) 1999-09-14 2000-09-13 Anti-proliferative medicaments that undergo preferential activation within the disease-affected cells and tissues
ZA200201081A ZA200201081B (en) 1999-09-14 2002-02-07 Phospholipid prodrugs of anti-proliferative drugs.
IL148554A IL148554A (en) 1999-09-14 2002-03-07 Pro-phospholipid drugs of antiproliferative drugs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL13188799A IL131887A0 (en) 1999-09-14 1999-09-14 Phospholipid prodrugs of anti-proliferative drugs

Publications (1)

Publication Number Publication Date
IL131887A0 true IL131887A0 (en) 2001-03-19

Family

ID=11073248

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13188799A IL131887A0 (en) 1999-09-14 1999-09-14 Phospholipid prodrugs of anti-proliferative drugs
IL148554A IL148554A (en) 1999-09-14 2002-03-07 Pro-phospholipid drugs of antiproliferative drugs

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL148554A IL148554A (en) 1999-09-14 2002-03-07 Pro-phospholipid drugs of antiproliferative drugs

Country Status (9)

Country Link
US (1) US6774121B1 (https=)
EP (1) EP1218013A4 (https=)
JP (1) JP2003514770A (https=)
AU (1) AU781507B2 (https=)
CA (1) CA2382633A1 (https=)
IL (2) IL131887A0 (https=)
NZ (1) NZ517522A (https=)
WO (1) WO2001019320A2 (https=)
ZA (1) ZA200201081B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135584B2 (en) 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
JP4259611B2 (ja) 1994-08-29 2009-04-30 ウェイク フォレスト ユニバーシティ ウィルス感染を治療するための脂質アナログ
US7026469B2 (en) * 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
US6670341B1 (en) 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
CN101979095A (zh) 2001-05-02 2011-02-23 普渡研究基金会 巨噬细胞介导的疾病的治疗和诊断
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US7410956B2 (en) * 2002-02-11 2008-08-12 Vertex Pharmaceuticals Incorporated Caspase inhibitor prodrugs
WO2003091264A2 (en) 2002-04-26 2003-11-06 Gilead Sciences, Inc. Non nucleoside reverse transcriptase inhibitors
US7432261B2 (en) 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7300924B2 (en) 2003-04-25 2007-11-27 Gilead Sciences, Inc. Anti-infective phosphonate analogs
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7470724B2 (en) 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
KR20060022647A (ko) 2003-04-25 2006-03-10 길리애드 사이언시즈, 인코포레이티드 키나아제 억제 포스포네이트 유사체
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
US7452901B2 (en) 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
US7407965B2 (en) 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
WO2004110250A2 (en) 2003-05-30 2004-12-23 Purdue Research Foundation Diagnostic method for atherosclerosis
WO2005044279A1 (en) 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
WO2005044308A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
WO2005042773A1 (en) 2003-10-24 2005-05-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
BRPI0417988A (pt) 2003-12-22 2007-04-27 Gilead Sciences Inc análogos de fosfonato antivirais
AU2005330489B2 (en) 2004-07-27 2011-08-25 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti HIV agents
EP1904183B1 (en) 2005-07-05 2014-10-15 Purdue Research Foundation Pharmaceutical composition for the treatment of osteoarthritis
DE102006019907A1 (de) * 2006-04-28 2007-10-31 Müller-Enoch, Dieter, Prof. Dr. Verwendung von substituierten Glycerinderivaten zur Herstellung einer pharmazeutischen Zubereitung
JP2010509570A (ja) 2006-11-03 2010-03-25 パーデュー・リサーチ・ファウンデーション エクスビボフローサイトメトリーの方法および装置
US8586595B2 (en) 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
WO2008148001A2 (en) 2007-05-25 2008-12-04 Purdue Research Foundation Method of imaging localized infections
US8658617B2 (en) 2008-07-08 2014-02-25 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
AU2011247358B2 (en) * 2010-04-30 2014-10-30 Urogen Pharma Ltd. Phospholipid drug analogs
US20120003298A1 (en) * 2010-04-30 2012-01-05 Alcide Barberis Methods for inducing an immune response
WO2012073245A1 (en) 2010-12-02 2012-06-07 Ben Gurion University Of The Negev Research And Development Authority Conjugates of a phospholipid and a drug for the treatment of inflammatory bowel disease
US9499800B2 (en) 2013-12-26 2016-11-22 Regents Of The University Of Minnesota Methods of making and using chemically self assembled-nanorings
CA2968145C (en) * 2014-11-17 2023-06-27 Cellectar Biosciences, Inc. Phospholipid ether analogs as cancer-targeting drug vehicles
SI3661937T1 (sl) 2017-08-01 2021-11-30 Gilead Sciences, Inc. Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb
CN112437674A (zh) * 2018-04-11 2021-03-02 新墨西哥科技大学研究园公司 用于药物递送的脂质前药
WO2025202629A1 (en) 2024-03-26 2025-10-02 Coopervision International Limited Contact lens loaded with a glycerophospholipid

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61152694A (ja) * 1984-12-27 1986-07-11 Toyama Chem Co Ltd 新規な５−フルオロ−２′−デオキシウリジン−５′−ホスフエ−ト誘導体およびその塩
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
ATE63124T1 (de) * 1986-03-14 1991-05-15 Fujisawa Pharmaceutical Co Prodrugverbindungen, verfahren zu deren herstellung und diese enthaltende zubereitungen mit verzoegerter freisetzung.
JPS6383093A (ja) * 1986-09-27 1988-04-13 Toyo Jozo Co Ltd ヌクレオシド−リン脂質複合体
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
WO1991016920A1 (en) 1990-05-07 1991-11-14 Vical, Inc. Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs
US5543389A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non Profit Organization Covalent polar lipid-peptide conjugates for use in salves
US5149794A (en) 1990-11-01 1992-09-22 State Of Oregon Covalent lipid-drug conjugates for drug targeting
AU668873B2 (en) 1991-07-12 1996-05-23 Chimerix, Inc. Antiviral liponucleosides: treatment of hepatitis B
IL105244A (en) 1993-03-31 2003-07-31 Dpharm Ltd Prodrugs with enhanced penetration into cells
US6413949B1 (en) * 1995-06-07 2002-07-02 D-Pharm, Ltd. Prodrugs with enhanced penetration into cells
US7517858B1 (en) * 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
CA2262624A1 (en) * 1996-08-02 1998-02-12 Smithkline Beecham Corporation A novel method of detecting and treating cancer
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
CA2320843A1 (en) * 1998-02-23 1999-08-26 Diadexus, Llc Methods using pla2 as a marker of metastases and for the diagnosis of selected cancers

Also Published As

Publication number Publication date
WO2001019320A3 (en) 2001-09-27
ZA200201081B (en) 2003-04-30
NZ517522A (en) 2003-08-29
CA2382633A1 (en) 2001-03-22
IL148554A (en) 2007-10-31
EP1218013A4 (en) 2004-12-15
AU7309300A (en) 2001-04-17
EP1218013A2 (en) 2002-07-03
WO2001019320A2 (en) 2001-03-22
JP2003514770A (ja) 2003-04-22
US6774121B1 (en) 2004-08-10
AU781507B2 (en) 2005-05-26

Similar Documents

Publication Publication Date Title
IL131887A0 (en) Phospholipid prodrugs of anti-proliferative drugs
AU1846702A (en) Anti-proliferative drugs
SG79255A1 (en) Pharmaceutical formulations
IL148558A0 (en) Amphiphilic prodrugs
IL149224A0 (en) Hydrogen-driven drug dosage form
CZ20011518A3 (cs) Farmaceutický prostředek
HUP0301164A3 (en) Method of administering bisphosphonates
PL342515A1 (en) Drug administering device
EG23858A (en) Drug combination
IL150053A0 (en) Pharmaceutical superdisintegrant
EP1087753A4 (en) TARGETED LIPOSOMAL DRUG ADMINISTRATION SYSTEM
EP1145714A4 (en) DRUGS
PL352062A1 (en) Oral solution of prucalopride
SI1296689T1 (sl) Nacin dajanja pacientu bisfosfonatov
IL148554A0 (en) Phospholipid prodrugs of anti-proliferative drugs
EP1114642A4 (en) MEDICAMENTS FOR THE TREATMENT OF PERIODONTAL DISEASES
GB9827865D0 (en) Medicament
IL126732A0 (en) Pro drug
IL127826A0 (en) Restenosis drug therapy
GB9818156D0 (en) Drug targeting
GB9818027D0 (en) Drug targeting I
IL156192A0 (en) Anti-proliferative drugs
GB9818030D0 (en) Drug targeting II
GB9811622D0 (en) Drug formulation
GB9827285D0 (en) Medicament